Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model
- PMID: 3661794
- PMCID: PMC1647098
- DOI: 10.2105/ajph.77.11.1417
Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model
Abstract
A computer simulation model was developed to project the future mortality, morbidity, and cost of coronary heart disease (CHD) in the United States population. The model contains a demographic-epidemiologic (DE) submodel, which stimulates the distribution of coronary risk factors and the conditional incidence of CHD in a demographically evolving population; a "bridge" submodel, which determines the outcome of the initial CHD event; and a disease history (DH) submodel, which simulates subsequent events in persons with a previous CHD event. The user of the model may simulate the effects of interventions, either preventive (i.e., risk factor modification) or therapeutic, upon mortality, morbidity, and cost for up to a 30-year period. If there were no future changes in risk factors or the efficacy of therapies after 1980, baseline projections indicate that the aging of the population, and especially the maturation of the post-World War II baby-boom generation, would increase CHD prevalence and annual incidence, mortality, and costs by about 40-50 per cent by the year 2010. Unprecedented reductions in risk factors would be required to offset these demographic effects on the absolute incidence of CHD. The specific forecasts could be inaccurate, however, as a consequence of erroneous assumptions or misestimated baseline data, and the model awaits validation based on actual future data.
Similar articles
-
The future impact of population growth and aging on coronary heart disease in China: projections from the Coronary Heart Disease Policy Model-China.BMC Public Health. 2008 Nov 27;8:394. doi: 10.1186/1471-2458-8-394. BMC Public Health. 2008. PMID: 19036167 Free PMC article.
-
The effect of risk factor reductions between 1981 and 1990 on coronary heart disease incidence, prevalence, mortality and cost.J Am Coll Cardiol. 2001 Oct;38(4):1012-7. doi: 10.1016/s0735-1097(01)01512-1. J Am Coll Cardiol. 2001. PMID: 11583874
-
Adolescent overweight and future adult coronary heart disease.N Engl J Med. 2007 Dec 6;357(23):2371-9. doi: 10.1056/NEJMsa073166. N Engl J Med. 2007. PMID: 18057339
-
Cost-effectiveness perspectives in coronary heart disease.Am Heart J. 1990 Mar;119(3 Pt 2):733-9; discussion 739-40. doi: 10.1016/s0002-8703(05)80054-7. Am Heart J. 1990. PMID: 1968700 Review.
-
Epidemiology of coronary heart disease.Am J Cardiol. 1967 Nov;20(5):692-702. doi: 10.1016/0002-9149(67)90013-6. Am J Cardiol. 1967. PMID: 4861320 Review. No abstract available.
Cited by
-
Gemfibrozil cost-benefit study. Targeting subgroups for effective hyperlipidaemia drug therapy.Drugs. 1990;40 Suppl 1:42-52. doi: 10.2165/00003495-199000401-00010. Drugs. 1990. PMID: 2127008 Clinical Trial.
-
Benefits of smoking cessation for longevity.Am J Public Health. 2002 Jun;92(6):990-6. doi: 10.2105/ajph.92.6.990. Am J Public Health. 2002. PMID: 12036794 Free PMC article.
-
A review of health care models for coronary heart disease interventions.Health Care Manag Sci. 2006 Nov;9(4):311-24. doi: 10.1007/s10729-006-9996-x. Health Care Manag Sci. 2006. PMID: 17186767 Review.
-
Cost-effectiveness of statins revisited: lessons learned about the value of innovation.Eur J Health Econ. 2012 Aug;13(4):445-50. doi: 10.1007/s10198-011-0315-1. Epub 2011 Apr 29. Eur J Health Econ. 2012. PMID: 21528389 Review.
-
The Habit Formation trial of behavioral economic interventions to improve statin use and reduce the risk of cardiovascular disease: Rationale, design and methodologies.Clin Trials. 2019 Aug;16(4):399-409. doi: 10.1177/1740774519846852. Epub 2019 May 31. Clin Trials. 2019. PMID: 31148473 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources